Candel Therapeutics (CADL) Common Equity (2020 - 2025)
Candel Therapeutics (CADL) posted Common Equity of $51.9 million for Q4 2025, down 35.2% sequentially from $80.1 million in Q3 2025, and down 21.72% YoY from $66.3 million in Q4 2024.
Candel Therapeutics (CADL) Common Equity (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Common Equity for 6 years, with the latest figure at $51.9 million in Q4 2025.
- Quarterly Common Equity fell 21.72% year-over-year to $51.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $51.9 million (down 21.72% YoY) and the FY2025 annual result came in at $51.9 million, down 21.72% from the prior year.
- Common Equity fell to $51.9 million in Q4 2025 per CADL's latest filing, from $80.1 million in the prior quarter.
- Over five years, Common Equity peaked at $90.2 million in Q2 2025 and troughed at -$43.2 million in Q2 2021.
- A 5-year average of $36.5 million and a median of $49.8 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity tumbled 249.85% in 2021, then soared 1148.95% in 2025.
- Over 5 years, Common Equity stood at $64.1 million in 2021, then slipped by 25.61% to $47.7 million in 2022, then plunged by 73.29% to $12.7 million in 2023, then surged by 420.42% to $66.3 million in 2024, then slipped by 21.72% to $51.9 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $51.9 million, $80.1 million, and $90.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 51.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.92 Mn |
| Sep 30, 2025 | 80.12 Mn |
| Jun 30, 2025 | 90.21 Mn |
| Mar 31, 2025 | 74.68 Mn |
| Dec 31, 2024 | 66.33 Mn |
| Sep 30, 2024 | -15.26 Mn |
| Jun 30, 2024 | -9.97 Mn |
| Mar 31, 2024 | 5.98 Mn |
| Dec 31, 2023 | 12.75 Mn |
| Sep 30, 2023 | 23.02 Mn |
| Jun 30, 2023 | 30.77 Mn |
| Mar 31, 2023 | 39.65 Mn |
| Dec 31, 2022 | 47.71 Mn |
| Sep 30, 2022 | 52.13 Mn |
| Jun 30, 2022 | 60.07 Mn |
| Mar 31, 2022 | 63.76 Mn |
| Dec 31, 2021 | 64.14 Mn |
| Sep 30, 2021 | 62.99 Mn |
| Jun 30, 2021 | -43.18 Mn |
| Mar 31, 2021 | -27.50 Mn |